Lv1
54 积分 2021-08-04 加入
Targeting AIF to trigger RIPKs/MLKL necroptosis: a disulfiram-based strategy to reverse paclitaxel resistance in ovarian cancer
9天前
已完结
2025 FDA approvals
2个月前
已完结
Reshaping Pfizer’s drug discovery priorities
2个月前
已完结
Bridging boundaries: making drug repurposing the new normal
2个月前
已完结
Trends in the landscape of clinical trials of innovative drugs in China since 2015
2个月前
已完结
Targeting claudins in cancer
2个月前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
2个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
2个月前
已完结
R&D productivity trends for biopharma companies in Asia and emerging markets
2个月前
已完结
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
2个月前
已完结
皖公网安备34019202002308
